<DOC>
	<DOC>NCT00560716</DOC>
	<brief_summary>This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Incurable advanced solid tumors that did not respond to conventional therapy or for which no effective therapy exists Age &gt;=18 years Eastern Cooperative Oncology Group (ECOG) performance status 02 Life expectancy â‰¥ 3 months Evaluable disease Adequate bone marrow function Adequate renal function Adequate liver function At least 3 weeks from prior systemic treatments including investigational anticancer therapy, radiation therapy; and have recovered from prior toxicities Able to swallow capsules At least 3 weeks from major surgery Agree to practice effective contraception Previously untreated CNS metastasis or progressive CNS metastasis documented by MRI scan performed at 4 weeks or longer after the last treatment for CNS metastasis Currently receiving radiotherapy, biological therapy, or any other investigational agents Uncontrolled intercurrent illness Pregnant or lactating women Known to be HIVpositive Known active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>